CVR Energy stock has significantly underperformed, with a -38% return in 2024. Check out why I maintain my Sell rating on CVI ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
GlobalData on MSN17h
Struggling bluebird bio to go private for less than $30mBluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a publicly traded company. The agreement comes after years of financial ...
Bluebird Bio (NASDAQ:BLUE) stock in focus as company intends to go private in M&A deal with Carlyle Group (CG) & SK Capital. Read more here.
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
Bluebird Bio has commercialized three gene therapy products, including one of the first for sickle cell disease, but would soon run out of cash.
ComicsPRO announcement that Bad Idea Comics joins Lunar Distribution for the launch of Death Planet in May 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback